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MYOCARDIAL ISCHEMIA AND REPERFUSION: 
THE ROLE OF OXYGEN RADICALS 
IN TISSUE INJURY 
SUMMARY. Thrombolyt ic  therapy has  gained widespread ac- 
ceptance as a means  of t r ea t ing  coronary ar tery  thrombosis  
in pa t ien ts  wi th  acute myocardial  infarct ion.  Although ex- 
per imenta l  da ta  have demonst ra ted  t ha t  timely reperfusion 
l imits the  extent  of infarct ion caused by regional  ischemia, 
there  is growing evidence tha t  reperfusion is associated wi th  
an  inf lammatory  response to ischemia tha t  exacerbates  the 
t issue injury.  Isehemic myocardium releases archidonate  
and  complement-derived chemotact ic  factors, e.g., leuko- 
t r iene B 4 and  Csa, which a t t r ac t  and act ivate  neutrophils .  
Reperfusion of ischemic myocardium accelerates the influx of 
neutrophi ls ,  which release react ive oxygen products,  such as 
superoxide anion and  hydrogen peroxide, resu l t ing  in the for- 
mat ion  of a hydroxyl radica l  and  hypochlorous acid. The lat-  
ter  two species may damage viable endothelial  cells and  
myocytes via the peroxidat ion of lipids and  oxidation of pro- 
te in  sulfhydryl groups, leading to per tu rba t ions  of membrane  
permeabi l i ty  and  enzyme function. Neutrophi l  depletion by 
an t i se rum and  inhibi t ion of neutrophi l  function by drugs,  
e.g., ibuprofen, p ros tag landins  (prostacyclin and PGE1), or a 
monoclonal antibody,  to the adherence-promoting glycopro- 
tein Mo-I receptor,  have  been shown to l imit  the extent  of 
canine  myocardial  injury due to coronary ar tery  occlusion/ 
reperfusion. Recent  studies have chal lenged the hypothesis  
that xanthine-oxidase-der ived oxygen radica ls  are a cause of 
reperfusion injury. Trea tmen t  wi th  al lopurinol  or oxypurinol 
may exert  beneficial  effects on isehemic myocardium tha t  are 
unre la ted  to the inhibi t ion o fxan th ine  oxidase. Fur thermore ,  
the h u m a n  hea r t  may lack xan th ine  oxidase activity. Fu r the r  
basic  research  is needed, therefore,  to clarify the importance 
of xan th ine  oxidase in the pathophysiology of reperfusion in- 
jury. Cur ren t  da ta  are  highly suggestive of a deleterious role 
of the  neutrophi l  in organ rcperfusion and justify considera- 
t ion of the cl inical  invest igat ion of neutrophi l  inhibi tors  in 
pa t ien ts  receiving thrombolyt ic  agents  dur ing  the evolution 
of an  acute myocardial  infarct ion.  
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Recognition that  coronary thrombosis is the pre- 
cipitating event in the onset of acute myocardial in- 
farction provided the rationale for exploring both phar- 
macologic and mechanical methods of restoring cor- 
onary artery patency [1]. Based on recent multicenter 
trials, which have demonstrated a reduction of mor- 
tality associated with the administration of throm- 
bolytic agents, thrombolytic therapy has become the 
standard of care for the treatment of acute myocardial 
infarction [2]. 
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The knowledge that  persistent myocardial ischemia 
leads to a time-dependent loss of viable myocardial 
tissue suggests that the early restoration of myocardial 
blood flow is essential in order to arrest the progression 
of myocardial cell death and to permit the functional 
recovery of reversibly injured myocardium. Reperfu- 
sion and reoxygenation of the ischemic myocardium, 
while essential for ultimate tissue survival, may be 
associated with the risk of extending the area of 
myocardial injury beyond that  which has occurred as a 
result of the ischemic process. The reintroduction of 
oxygenated blood to the previously ischemic myocar- 
dial tissue may be detrimental to the survival of the 
reoxygenated cell, as well as beneficial. A major effort 
has been expended in recent years to gain a better un- 
derstanding of the phenomena that  have been referred 
to as the oxygen paradox [3-5] and reperfusion injury 
[5, 6]. The suggestion has been made that  oxygen 
radicals are involved in both processes [4-6]. Extensive 
research has been devoted toward reducing the extent 
of tissue injury associated with ischemia and reperfu- 
sion by modifying the sequence of events that  are 
thought to be involved in the generation of oxygen free 
radicals. Several authors have reviewed recent studies 
that  support the concept of oxygen-radical-mediated 
reperfusion injury [5-9]. This review will focus on the 
role of oxygen free radicals in the extension of cardiac 
injury during reperfusion after regional myocardial 
ischemia and, in particular, on the important role of 
the polymorphonuclear leukocyte as a primary medi- 
ator of reperfusion injury due to its capacity to generate 
reactive species of oxygen. 
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Oxidative Stress 
All mammalian cells are subjected to free radical reac- 
tions that occur continuously in vivo as a result of both 
enzymatic and nonenzymatic mechanisms, although 
the former is most likely the more important reactive 
process. Oxidative stress occurs in cells and tissues 
when there is an increase in the rate of generation of su- 
peroxide anion (02) and hydrogen peroxide (H202) 
that exceeds the capacity of the endogenous cellular 
defenses. Enhanced production of 02 can occur in 
tissues as a result of an increase in the oxygen tension, 
the presence of toxic substances that increase in- 
tracellular oxidant formation (e.g., adriamycin, aceto- 
minophen, paraquat), or as a result of the activation of 
specific enzymatic mechanisms that are capable of 
leading to the formation of 02 (NADPH-oxidase in 
neutrophils or xanthine oxidase) [8, 9]. Thus, the ac- 
cumulation of inflammatory cells at a site of ischemic 
injury may contribute to an extension of the cellular 
destruction by mechanisms unrelated to oxygen 
deprivation. 
H202 exerts an oxidant stress by virtue of its conver- 
sion via a metal ion-dependent reaction to the hydroxyl 
radical (OH-). The latter reaction is enhanced by the 
presence of 02. The extreme reactivity of OH. limits 
its interaction with biomolecules to diffusion con- 
trolled reactions, so that the reactive species of oxygen 
must interact with its target close to the site at which it 
is formed. In this instance, iron ions are considered to 
be the most likely promoters of OH. ion formation [10, 
11]. The source of iron may come from ferritin when it 
reacts with O~ [12] and/or from hemoglobin, which is 
degraded in the presence of H202 [13]. 
Antioxidant Mechanisms 
Aerobic cells have the capacity to remove the reactive 
products of oxygen that are formed during normal 
metabolic events. The primary intracellular defense 
mechanisms against oxidative stress include superox- 
ide dismutase, glutathione peroxidase, catalase, and 
vitamin E localized in the lipid membrane. Superoxide 
dismutase is present in the mitochondria of mam- 
malian cells as manganese superoxide dismutase and 
in the cytosol as a copper-zinc form of the enzyme. The 
enzyme catalzyes the following reaction: 
202 + 2H ÷ -* 02 + H202. 
The rate constant for the reaction shown above is suf- 
ficiently rapid so that little if any superoxide anion is 
available to react with the hydrogen peroxide, which 
might otherwise lead to the formation of hydroxyl 
anion via the metal-catalyzed Haber-Weiss reaction 
shown below: 
H202 + Fe 2+-* OH. + OH- + Fe 3+ 
02 + Fe3+--* 02 + Fe 2+. 
The decomposition of hydrogen peroxide to water and 
oxygen can be catalyzed by the enzymes catalase and 
glutathione peroxidase. The latter enzyme also cat- 
alyzes the reduction of lipid peroxides. The reduction 
of hydrogen peroxide or lipid peroxides by glutathione 
peroxidase is accompanied by the oxidation of gluta- 
thione, resulting in the formation of glutathione dis- 
fulfide. Glutathione is regenerated from glutathione 
disfulfide by glutathione reductase; but under con- 
ditions of excessive oxidative stress, regeneration of 
glutathione may be inadequate to prevent the perox- 
idation of membrane lipids [14]. 
Whereas the intracellular compartment contains 
several antioxidant mechanisms, the main extra- 
cellular defense against free radicals resides with the 
copper-containing protein, ceruloplasmin [8]. Several 
studies, however, have demonstrated that erythrocytes 
may remove extracellular hydrogen peroxide, thereby 
protecting surrounding tissue against damage medi- 
ated by hydrogen peroxide or its secondary products, 
hydroxyl anion and hypochlorous acid [15-17]. The 
latter oxidant is produced by neutrophil-derived 
myeloperoxidase. Erythrocytes were shown to prevent 
the oxidation of cytochrome C, damage to cultured en- 
dothelial cells, and lung edema caused by exogenous 
hydrogen peroxide [15]. The inhibition of erythrocyte 
catalase abolished the protection afforded by erythro- 
cytes, and the addition of purified catalase restored 
protection [16]. Erythrocytes were unable to inhibit 
the oxidation of cytochrome C by superoxide anions 
[17], and the inhibition of erythrocyte superoxide dis- 
mutase did not affect the ability of erythrocytes to pre- 
vent xanthine-oxidase-induced injury of target cells 
[16]. Thus, erythrocytes would be expected to provide 
other cells or tissues protection from hydrogen perox- 
ide, but not from superoxide anions generated in their 
environment [17]. The fact that plasma and/or blood 
may provide an effective antioxidant defense against 
the presence of extracellular hydrogen peroxide but not 
superoxide anions suggests that the exogenous addi- 
tion of superoxide dismutase could modulate reactions 
of the free radical species of oxygen, while the addition 
of catalase may not. This has been suggested by the ob- 
servation that superoxide dismutase alone was found 
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to limit ischemic myocardial injury in vivo, whereas 
catalase was without benefit [18]. 
Myocardial Ischemia and Leukocytes 
Myocardial infarction is associated with an inflam- 
matory response that has been regarded previously as a 
repair process that replaces necrotic tissue with a 
collagenous scar. Recently, there has been growing 
recognition that the injury associated with the infiltra- 
tion of polymorphonuclear leukocytes during ischem- 
ia, and especially upon reperfusion, could be additive 
to that resulting from the ischemic process itself. The 
infiltration of ischemic canine myocardium by neu- 
trophils begins within 60 minutes of coronary occlusion 
and is enhanced significantly by reperfusion [19, 20]. 
The hypothesis that neutrophils contribute to the 
extension of ischemic damage and participate in reper- 
fusion injury is supported by numerous studies that 
have demonstrated that agents that inhibit neutrophil 
function or interfere with the products of neutrophils 
limit myocardial injury in experimental animals sub- 
jected to coronary artery occlusion followed by reperfu- 
sion [7]. Romson et al. [21] examined the effect of an 
antineutrophil antiserum on the extent of canine 
myocardial injury due to regional ischemia for 90 
minutes followed by reperfusion for 6 hours. Dogs 
treated with the antiserum showed a 77% reduction in 
the blood leukocyte count and 43% smaller infarcts 
compared to dogs treated with a nonimmune serum. 
There were no hemodynamic effects of the antiserum 
to account for the reduction of infarct size, indicating 
that the limitation of myocardial injury was related to 
the neutropenic state. Subsequently, Mullane et al. 
[22] observed that a 60% reduction in the circulating 
neutrophil count induced by treatment with hydroxy- 
urea resulted in a significant decrease in canine 
myocardial injury due to coronary artery occlusion 
and reperfusion. 
Drugs that inhibit neutrophil function without 
causing neutropenia have also been shown to be car- 
dioprotective during experimental regional myocar- 
dial ischemia and reperfusion. Romson et al. [23] 
demonstrated that the reduction of canine myocardial 
infarct size by ibuprofen, for example, was associated 
with a decreased accumulation of neutrophils in the 
reperfused ischemic myocardium. Flynn et al. [24] 
studied the effects of ibuprofen and aspirin on feline 
neutrophil function and myocardial infarction. Ibu- 
profen, but not aspirin, inhibited the respiratory burst 
of activated neutrophils and reduced the extent of 
myocardial damage. Thus, the cardioprotective effects 
of the nonsteroidal antiinflammatory agents are 
related to the inhibition of neutrophil function, rather 
than the inhibition of the cyclooxygenase pathway. 
Simpson and colleagues [25-27] have investigated 
the mechanism by which prostaglandin E1 (PGE1), 
prostacyclin (PGI2), and iloprost, a stable analog of 
PGI2, salvage reperfused ischemic myocardium. Each 
agent was found to inhibit the generation of superoxide 
anions by activated neutrophils in vitro and to limit 
canine myocardial injury caused by coronary artery oc- 
clusion and reperfusion in vivo. The compound 
SC39902, another stable analog of PGI2, exerted 
hemodynamic effects similar to PGI2, but did not 
reduce infarct size or inhibit neutrophil function [25], 
suggesting that PGI2, PGI 1, and iloprost limit reper- 
fusion injury by suppressing neutrophil-mediated 
tissue damage. 
Complement and Leukotriene B4 
The complement system serves a major role in the pro- 
duction of mediators involved in the acute inflam- 
matory response. Chemotactic factors that are gener- 
ated by the activation of the complement system, e.g., 
C3~, participate in the recruitment and activation of 
neutrophils, whereas the anaphylatoxins, e.g., C~a, 
mediate changes in vascular permeability. Enzymes 
may react with individual complement components, 
resulting in the formation of inflammatory mediators, 
without causing generalized activation of the comple- 
ment cascade [28, 29]. Hill and Ward [28, 29] 
demonstrated the presence of a tissue protease in 
ischemic myocardium that cleaves the third compo- 
nent of complement into chemotactically active 
fragments that may stimulate the attraction of neutro- 
phils to the myocardium. Other investigators have 
focused attention on the ability of mitochondria and 
cardiac subcellular membranes to activate the comple- 
ment system [30-33]. Rossen and coworkers [33] have 
presented evidence that the cardiac lympatic drainage 
during postischemic reperfusion contains molecules of 
cardiac subcellular origin that are bound to Clq. The 
authors postulate that the formation of macro- 
molecular complexes may be one of the stimuli that 
provokes the inflammatory response to myocardial 
ischemia. The concept that myocardial ischemia is 
associated with complement-induced injury that is 
mediated by neutrophils is supported by experiments 
which showed that depletion of complement by treat- 
ment with cobra venom factor limits both the influx of 
neutrophils and the release of creatine kinase by 
ischemic myocardium [34]. 
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Neutrophils trapped within the vascular capillary 
bed, as well as those that have extravasated into the ex- 
travascular space, are capable of attracting and ac- 
tivating additional phagocytic cells through their abili- 
ty to synthesize lipoxygenase metabolites of arachi- 
donic acid, including leukotriene B4 (LTB4), one of the 
most potent neutrophil chemoattractants. LTB 4 am- 
plifies the neutrophil-mediated injury by stimulating 
the chemotaxis of neutrophils and their release of reac- 
tive oxygen species. The tissue concentration of LTB4 
and other eicosanoids is greatly increased in myocar- 
dium that has undergone regional ischemia [22, 35], 
and in one study the peak concentration of LTB 4 pre- 
ceded the peak influx of neutrophils, suggesting that 
the myocardium itself may produce LTB4 during 
ischemia [35]. Drugs that inhibit the 5-1ipoxygenase 
pathway, such as BW 755C and nafazatrom, have been 
shown to reduce neutrophil infiltration and tissue 
damage of the ischemic/reperfused myocardium [22, 
36, 37]. BW 755C and nafazatrom, however, display 
multiple pharmacologic effects, and the study of pure 
lipoxygenase inhibitors and leukotriene antagonists 
will be necessary to clarify the importance of leuko- 




Leukocyte attachment to target cells may be a pre- 
requisite for neutrophil-mediated cellular injury. 
Leukocytes have cell-surface glycoprotein complexes, 
referred to as the CDwl8 complex or LFA antigens, 
that are involved in cell-cell and cell-surface interac- 
tions [38-40]. The adherence molecules are hetero- 
dimers, consisting of common beta subunits with dif- 
ferent alpha subunits that dictate the molecular 
specificity. The Mo-1 complex, a heterodimer present 
on both human and animal (canine, nonhuman 
primates) phagocytic cells, is functionally very similar, 
or may be identical, to the C3bi receptor (CR3), which 
mediates adherence to cells coated with C3bi. Activa- 
tion of neutrophils increases the expression of the 
adhesion-promoting receptors [41]. Using monoclonal 
antibodies directed against the Mo-1 glycoprotein 
complex, it was demonstrated that the Mo-1 receptor 
is responsible for the attachment of neutrophils to a 
variety of substrates, including vascular endothelium 
and pulmonary alveolar epithelium [42]. An anti-Mo-1 
monoclonal antibody not only prevented the adherence 
of neutrophils to pulmonary alveolar epithelial cells, 
but reduced the extent of cell injury caused by the 
neutrophils [42]. 
The same anti-Mo-1 monoclonal antibody was used 
to further investigate the contribution of neutrophils to 
myocardial injury caused by ischemia and reperfusion. 
Administration of the anti-Mo-1 antibody 45 minutes 
after the induction of regional myocardial ischemia 
significantly reduced the extent of myocardial injury in 
dogs subjected to coronary artery occlusion for 90 
minutes, followed by reperfusion for 6 hours [43]. The 
antibody had no effect on arterial blood pressure, heart 
rate, or coronary artery blood flow, which could ac- 
count for the observed protective effect. The results in- 
dicate that neutrophil adhesive interactions are an im- 
portant step in neutrophil-mediated myocardial injury 
and that the extent of myocardial damage may be 
reduced by inhibiting neutrophil adhesive interac- 
tions. These observations provide additional evidence 
for the important role of inflammatory cells in extend- 
ing myocardial injury beyond that caused by the 
ischemic interval itself. 
Mediators of Leukocyte-Induced 
Myocardial Injury 
Neutrophils that accumulate within the reperfused 
myocardium may exert deleterious effects via several 
mechanisms. Compared to erythrocytes, neutrophils 
are less deformable and more susceptible to trapping in 
the microcirculation during ischemia [44]. Engler et al. 
[44] observed that 60% of the capillaries in the region of 
myocardium subjected to ischemia and reperfusion 
were obstructed by leukocytes and displayed evidence 
of the "no reflow" phenomenon. The authors pos- 
tulated that failure to maintain reflow to the previous- 
ly ischemic myocardial region was related to the pro- 
gressive obstruction of the capillary bed by the 
accumulating neutrophils that adhered to the endo- 
thelial surface of the vasculature. Thus, mechanical 
plugging of capillaries, resulting in the "no reflow" 
phenomenon, is one mechanism by which neutrophils 
may exacerbate ischemic myocardial injury. 
Proteases 
Once attached to the vascular endothelium, neutro- 
phils are capable of becoming fully activated by com- 
plement products, leukotriene B4, or platelet-activat- 
ing factor, releasing destructive proteases and toxic 
oxygen products. The human neutrophil contains two 
latent metalloproteinases, collagenase and gelatinase, 
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which are released upon activation of the cell and 
which are activated by hypochlorous acid. Treatment 
with aprotinin, a nonspecific inhibitor of proteolysis, 
limited the extent of canine myocardial infarction, 
suggesting that lysosomal proteases may participate in 
the progressive destruction of otherwise viable myocar- 
dial tissue [45]. Aprotinin also exerts a direct in- 
hibitory effect on neutrophils, however, that may ac- 
count for its cardioprotective property [46]. Bolli et al. 
[47] were unable to confirm the observation regarding 
the deleterious role of proteolytic lysosomal enzymes as 
mediators of ischemic myocardial injury. Thus, the 
relationship between lysosomal enzymes and ischemic 
myocardial injury remains unsettled and requires 
further assessment. 
Oxygen Radicals 
The activation of neutrophils by chemotactic factors, 
such as C5~, platelet activating factor, or leukotriene 
B4, stimulates the NADPH oxidase of the neutrophil 
cell membrane to catalyze the univalent reduction of 
oxygen to yield superoxide anion, an oxygen free radi- 
cal capable of giving rise to other activated products of 
oxygen such as hydrogen peroxide and hydroxyl anion. 
The latter may be derived from the interaction of hy- 
drogen peroxide with lactoferrin, another product 
released by activated neutrophils [48]. Neutrophil- 
derived myelperoxidase catalyzes the reaction of hy- 
drogen peroxide with chloride anions, forming hypo- 
chlorous acid, a highly reactive oxidant [49]. The oxy- 
gen metabolites released by activated neutrophils have 
been shown to cause peroxidation of membrane lipids, 
denaturation of proteins, and degradation of intersti- 
tial matrix molecules, resulting in altered membrane 
permeability and enzymatic activity [50]. 
Numerous studies have been conducted to inves- 
tigate the effects of oxygen radical scavengers on exper- 
imental myocardial injury due to regional or global 
ischemia. Jolly et al. [51] examined the effect of con- 
comitant treatment with superoxide dismutase 
(SOD), an enzyme that dismutates superoxide anion, 
and catalase, an enzyme that degrades hydrogen 
peroxide on myocardial injury in dogs undergoing oc- 
clusion of the left circumflex coronary artery for 90 
minutes, followed by reperfusion for 24 hours. In- 
fusions of SOD in combination with catalase, started 
either 15 minutes before coronary occlusion or 15 
minutes before reperfusion, were equally effective in 
reducing myocardial tissue damage, suggesting that 
oxygen-radical-mediated injury is temporally related 
to the onset of reperfusion. Subsequently, treatment 
with SOD alone was compared to treatment with 
catalase alone using the same experimental prepara- 
tion [18]. Dogs receiving SOD alone had 50% smaller 
infarcts than control dogs, while catalase had no 
significant beneficial effect on infarct size, suggesting 
that reperfused ischemic myocardium is susceptible to 
superoxide-anion-mediated damage. The failure of 
catalase to reduce myocardial injury may relate to the 
abundant catalase activity of erythrocytes, which are 
capable of detoxifying hydrogen peroxide, but not su- 
peroxide anions, produced in the local environment 
[17]. Thus, blood-perfused systems subjected to is- 
chemia and reperfusion may be protected from hy- 
drogen peroxide, but unable to detoxify superoxide 
anions due to the relative absence of protective 
mechanisms in the interstitial space where invading 
leukocytes react with the surrounding tissues and 
release cytotoxic oxygen intermediates. 
The action of SOD is presumed to occur at sites of 
superoxide anion radical formation, where neutrophils 
adhere to endothelial cell membranes or extravasate 
into the extravascular space. Treatment with SOD 
that was delayed until 40 minutes after coronary artery 
reperfusion, however, did not reduce myocardial in- 
jury, suggesting that the cellular damage produced by 
oxygen radicals occurs upon, or soon after, reper- 
fusion--perhaps before the peak accumulation of neu- 
trophils exiting from the vascular compartment into 
the interstitial space [51]. Furthermore, recent studies 
have arrived at conflicting conclusions regarding the 
ability of SOD to limit the extent of experimental 
myocardial infarction. Werns et al. [52] and Ambrosio 
et al. [53] reported that treatment with SOD reduced 
infarct size in dogs subjected to coronary artery occlu- 
sion for 90 minutes followed by reperfusion for 24 hours 
[52] or 48 hours [53]. When the extent of myocardial in- 
jury due to 90 minutes of ischemia was assessed after 4 
days [54] or 7 days [55] of reperfusion, a beneficial ef- 
fect of treatment with "native" SOD was not demon- 
strable, but treatment with PEG-SOD, which has a 
prolonged plasma half-life due to the polyethylene 
glycol conjugate, was found to significantly reduce the 
extent of infarction after coronary artery occlusion for 
90 minutes, followed by reperfusion for 7 days [56]. The 
latter study implies that effective therapy directed 
against damage caused by oxygen radicals requires an 
agent with a prolonged duration of action. Similarly, 
Simpson et al. [57] found that sustained limitation of 
myocardial injury by treatment with iloprost, a prosta- 
cyclin analogue that inhibits neutrophil function, re- 
quires treatment extending beyond the first several 
hours after coronary artery reperfusion. 
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The Role of Xanthine Oxidase 
in Myocardial Reperfusion Injury 
The enzyme xanthine oxidase is an additional pro- 
posed source of oxygen radicals within reperfused 
ischemic myocardium. Chambers et al. [58] reported 
that myocardial ischemia causes the conversion of 
myocardial xanthine dehydrogenase, which does not 
utilize oxygen as a substrate, to xanthine oxidase, 
which can reduce oxygen to superoxide anion and hy- 
drogen peroxide. They hypothesized that xanthine oxi- 
dase utilizes hypoxanthine and xanthine as substrates 
to generate superoxide anions during reperfusion of 
ischemic myocardium. Dogs treated with allopurinol, 
an inhibitor of xanthine oxidase, beginning 1 day 
before temporary coronary artery occlusion, had 
significantly smaller infarcts than control dogs, sup- 
porting the hypothesis. Using a dosing protocol similar 
to that employed by Chambers et al. [58], experiments 
performed in this laboratory demonstrated a 40% 
reduction of myocardial injury after coronary artery 
occlusion for 90 minutes, followed by reperfusion for 6 
hours [59]. 
Additional studies have contradicted the conclusion 
that xanthine oxidase inhibition reduces the extent of 
regional myocardial injury in the dog. Reimer and Jen- 
nings [60] did not observe a favorable effect of 
allopurinol in dogs subjected to coronary artery occlu- 
sion for 40 minutes, followed by reperfusion for 4 days. 
The latter study differed from previous studies because 
allopurinol treatment did not commence until 30 
minutes before coronary artery occlusion. Subsequent- 
ly, a study performed by the authors showed that treat- 
ment with allopurinol beginning 15 minutes before 
reperfusion failed to limit myocardial injury in dogs 
subjected to 90 minutes of coronary artery occlusion 
followed by 6 hours of reperfusion [61]. Oxypurinol, a 
metabolite of allopurinol that has a prolonged plasma 
half-life and acts as a noncompetitive inhibitor of 
xanthine oxidase, significantly reduced the extent of 
injury when the drug was administered both 15 
minutes before reperfusion and 3 hours after reperfu- 
sion [61]. Several additional laboratories have ex- 
amined the effect of oxypurinol on canine myocardial 
infarction [62-64]. Studies conducted by Matsuki et 
al. [62] and Puett et al. [63] employed a protocol con- 
sisting of coronary artery occlusion for 90 minutes 
followed by reperfusion for 24 hours. Treatment with 
either allopurinol or oxypurinol administered as a 
bolus of 10 mg/kg 15 minutes before reperfusion, 
followed by an infusion of 55 mg/kg/day for 1 day, 
caused a marked and similar limitation of infarct size 
[62]. When oxypurinol therapy was limited to a 25-rag/ 
kg dose 30 minutes before reperfusion, there was no 
detectable effect on the extent of infarction [63]. 
Similarly, the administration of oxypurinol, 10 mg/kg, 
10 minutes before occlusion and 10 minutes before 
reperfusion, failed to alter the size of infarction in dogs 
subjected to coronary artery occlusion for 40 minutes 
and reperfusion for 4 days [64]. Thus, the data regard- 
ing the effects of both allopurinol and oxypurinol on 
canine infarct size are conflicting, perhaps due to the 
different schedules of drug administration. Treatment 
with oxypurinol that ceased at the time of reperfusion 
was ineffective [63, 64], while therapy that was main- 
tained throughout reperfusion until the time of sac- 
rifice significantly reduced the extent of injury [61, 62]. 
Analagous results were obtained in dogs treated with 
iloprost, a prostacylin analog [57]. 
Although experiments performed in our laboratory 
found that the administration of allopurinol 15 min- 
utes before reperfusion did not reduce the extent of 
myocardial injury, the efflux of uric acid from the cor- 
onary sinus during reperfusion was equally suppressed 
by allopurinol and oxypurinol, suggesting that cardiac 
xanthine oxidase activity was inhibited [61]. Inde- 
pendent laboratories have reported that xanthine oxi- 
dase activity is undetectable in the rabbit heart [65- 
68] or the pig heart [69], although several studies have 
concluded that allopurinol limited ischemic myocar- 
dial injury in the rabbit [66, 70] and pig [69]. Thus, 
multiple studies suggest that allopurinol and oxy- 
purinol may exert salutory effects on myocardial injury 
that are unrelated to the inhibition of xanthine oxi- 
dase. Peterson et al. [71] have proposed that allopuri- 
nol might facilitate electron transfer between the com- 
ponents of the respiratory chain within ischemic 
mitochondria. Other data indicate that allopurinol 
and oxypurinol may act as scavengers of reactive oxy- 
gen metabolites, including hydroxyl radical and 
hypochlorous acid [69, 72, 73]. This view is not shared 
by all investigators, as suggested by a recent study [74] 
which demonstrated that allopurinol does not produce 
its beneficial effects by scavenging oxidants produced 
in the extracellular fluid by activated neutrophils. 
No xanthine oxidase activity was detected by 
biochemical analysis of human myocardium [75, 76], 
although immunohistochemical studies purported to 
demonstrate the enzyme in the capillary endothelial 
cells of most organs, including the human heart [77]. 
Thus, further research is required to clarify the impor- 
tance of xanthine oxidase in the pathogenesis of post- 
ischemic myocardial injury. 
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Conclusions 
There are mul t ip le  potent ia l  sources of oxygen radicals 
dur ing  the reperfusion of ischemic myocardium.  There 
are contradictory da ta  regarding the impor tance  of 
xanthine-oxidase-der ived free radicals in the patho- 
genesis of reperfusion injury.  A b u n d a n t  evidence sug- 
gests t ha t  neutrophi ls  a t t rac ted  to ischemic myocar- 
d ium by eicosanoids and  complement-der ived pep- 
t ides damage viable tissue via the generat ion of 
cytotoxic species of oxygen. Thus,  agents  tha t  are 
directed against  the mechan i sms  of neut rophi l  chemo- 
taxis and  act ivat ion,  such as prostacyclin and  ant i-  
Mo-1 antibodies,  may  be worthy of clinical investiga- 
t ion in  pa t ien ts  receiving thrombolyt ic  agents  during 
acute myocardial  infarction.  
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